drugset / Trial / NCT05063058
Biomarker-driven Therapy for Melanoma
Completed
100 enrolled
Charite University, Berlin, Germany
Alacris · collabMax-Planck Institut · collab
NaSingle-groupOpen-labelBasic science
Summary
Patients included will undergo biopsy and the molecular analysis will be discussed at the institutional molecular tumor board. The recommandation of the molecular tumor board will be provided to the physician in charge of the patient for final treatment desicion. The main endpoints are the number of patients with actionable molecular alterations, the number of patients with a treatment recommendation, the number of patients receiving the recommended therapy, overall survival of the patients treated according to recommendations or not. For patients treated according to the recommendations: Response rate and progression free survival at 6 months according to RECIST criteria.
Timeline
- Start
- 2016-01
- Primary completion
- 2019-11
- Completion
- 2021-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 60 mg | — |
| Subject | Crizotinib | Small molecule | 250 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |
| Subject | Palbociclib | Small molecule | 125 mg | — |
| Subject | Selumetinib | Small molecule | 75 mg | — |
| Subject | Sorafenib | Small molecule | 400 mg | — |
| Subject | Trametinib | Small molecule | 2 mg | — |